Appendix Table.
Fixed effects estimates of the hierarchical logistic regression model used for calculating hospital risk-standardized utilization rates of nesiritide
| Variables | OR (95% CI) | p-value |
|---|---|---|
| Time points (quarter) | ||
| 1 | 21.1 (16.4–27.1) | <.0001 |
| 2 | 15.4 (11.9–19.8) | <.0001 |
| 3 | 8.7 (6.7–11.3) | <.0001 |
| 4 | 6.3 (4.8–8.1) | <.0001 |
| 5 | 4.8 (3.7–6.2) | <.0001 |
| 6 | 4.6 (3.5–5.9) | <.0001 |
| 7 | 3.8 (2.9–4.9) | <.0001 |
| 8 | 3.6 (2.7–4.6) | <.0001 |
| 9 | 3.3 (2.6–4.3) | <.0001 |
| 10 | 3.5 (2.7–4.6) | <.0001 |
| 11 | 3.2 (2.5–4.2) | <.0001 |
| 12 | 3.1 (2.4–4.1) | <.0001 |
| 13 | 2.6 (2.0–3.4) | <.0001 |
| 14 | 2.6 (2.0–3.4) | <.0001 |
| 15 | 2.5 (1.9–3.2) | <.0001 |
| 16 | 2.4 (1.8–3.1) | <.0001 |
| 17 | 1.9 (1.5–2.5) | <.0001 |
| 18 | 1.8 (1.4–2.4) | <.0001 |
| 19 | 1.6 (1.2–2.2) | 0.0006 |
| 20 | 1.4 (1.1–1.9) | 0.01 |
| 21 | 1.3 (1.0–1.8) | 0.0424 |
| 22 | 1.3 (1.0–1.7) | 0.101 |
| 23 | 1.0 (0.8–1.4) | 0.7969 |
| 24 | 1.0 (.–.) | . |
| Age Group | ||
| 18 – 24 | 2.1 (1.6–2.6) | <.0001 |
| 25 – 34 | 1.5 (1.3–1.7) | <.0001 |
| 35 – 44 | 1.4 (1.3–1.5) | <.0001 |
| 45 – 54 | 1.3 (1.2–1.3) | <.0001 |
| 55 – 64 | 1.3 (1.2–1.3) | <.0001 |
| 65 – 74 | 1.2 (1.1–1.2) | <.0001 |
| 75 – 99 | 1.0 (.–.) | . |
| Gender | ||
| Female | 0.8 (0.8–0.8) | <.0001 |
| Male | 1.0 (.–.) | . |
| Race | ||
| White | 1.1 (1.1–1.2) | 0.0001 |
| Black | 1.2 (1.2–1.3) | <.0001 |
| Hispanic | 1.1 (1.0–1.2) | 0.1077 |
| Other | 1.0 (.–.) | . |
| Elixhauser Comorbidity | ||
| Valvular disease | 1.2 (1.1–1.3) | 0.0002 |
| Pulmonary circulation disease | 0.8 (0.8–0.9) | 0.0005 |
| Peripheral vascular disease | 1.0 (0.9–1.1) | 0.3963 |
| Hypertension | 0.9 (0.8–0.9) | <.0001 |
| Paralysis | 0.8 (0.7–0.9) | <.0001 |
| Other neurological disorders | 0.8 (0.7–0.8) | <.0001 |
| Chronic pulmonary disease | 0.9 (0.9–1.0) | <.0001 |
| Diabetes w/o chronic complications | 1.2 (1.1–1.2) | <.0001 |
| Diabetes w/chronic complications | 1.2 (1.2–1.3) | <.0001 |
| Hypothyroidism | 1.1 (1.0–1.1) | 0.001 |
| Renal failure | 1.4 (1.3–1.4) | <.0001 |
| Liver disease | 1.0 (0.9–1.1) | 0.9721 |
| Peptic ulcer Disease x bleeding | 0.7 (0.4–1.4) | 0.361 |
| Acquired immune deficiency syndrome | 0.6 (0.4–0.8) | 0.0002 |
| Lymphoma | 0.9 (0.8–1.1) | 0.3999 |
| Metastatic cancer | 0.7 (0.6–0.8) | <.0001 |
| Solid tumor w/out metastasis | 0.8 (0.7–0.9) | <.0001 |
| Rheumatoid arthritis/collagen vas | 0.9 (0.8–1.0) | 0.0095 |
| Coagulopthy | 1.2 (1.2–1.3) | <.0001 |
| Obesity | 1.1 (1.0–1.1) | <.0001 |
| Weight loss | 1.2 (1.1–1.3) | <.0001 |
| Fluid and electrolyte disorders | 1.4 (1.3–1.4) | <.0001 |
| Chronic blood loss anemia | 0.9 (0.8–1.0) | 0.0686 |
| Deficiency Anemias | 1.0 (1.0–1.1) | 0.0256 |
| Alcohol abuse | 1.1 (1.0–1.1) | 0.1291 |
| Drug abuse | 1.0 (0.9–1.1) | 0.6205 |
| Psychoses | 0.8 (0.8–0.9) | <.0001 |
| Depression | 0.9 (0.8–0.9) | <.0001 |
| Other AHRQ Comorbidity | ||
| Disorders of lipid metabolism | 1.0 (1.0–1.1) | 0.0003 |
| Coronary atherosclerosis and other heart disease | 1.4 (1.4–1.5) | <.0001 |
| Acute myocardial infarction | 1.4 (1.3–1.5) | <.0001 |
| Peripheral and visceral atherosclerosis | 1.1 (1.0–1.3) | 0.0307 |
| Aortic; peripheral; and visceral artery aneurysms | 1.1 (1.0–1.2) | 0.1274 |
| Aortic and peripheral arterial embolism or thrombosis | 1.1 (0.9–1.4) | 0.254 |
| Transient cerebral ischemia | 0.8 (0.6–1.0) | 0.0568 |
| Cardiac dysrhythmias | 1.3 (1.3–1.3) | <.0001 |
| Cardiac arrest and ventricular fibrillation | 1.1 (1.0–1.3) | 0.0023 |